Viyash Scientific reported a significant acceleration in profitability for the first quarter of FY26, with consolidated net profit after tax surging 115% year-on-year to ₹792.90 million. The Board of Directors approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, during a meeting held on August 11, 2026. Revenue from operations expanded 19.5% to ₹9,463.60 million, while EBITDA rose to ₹1.48 billion from ₹1.18 billion in the corresponding period last year, with EBITDA margin expanding to 18.9% from 14.98%. This performance reflects improved operational efficiency and strong top-line growth across its pharmaceutical portfolio.

The financial results were reviewed by Statutory Auditors SRBC & Co LLP in accordance with Standard on Review Engagements (SRE) 2410 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The comparative figures for the previous year have been restated to reflect the Composite Scheme of Amalgamation with Viyash Life Sciences Private Limited and other entities, sanctioned by the National Company Law Tribunal (NCLT) on November 18, 2025. The amalgamation was accounted for using the pooling of interest method under Appendix C of Ind AS 103.

Q1FY26 Financial Highlights

The following table outlines the key consolidated financial metrics for the quarter:

Standalone revenue stood at ₹3,536.90 million, up from ₹3,281.80 million in Q1FY25, while standalone net profit rose to ₹209.20 million from ₹173.00 million. Total expenses increased to ₹8,422.60 million from ₹7,488.90 million, driven largely by higher cost of materials consumed and employee benefits expenses.

Strategic Approvals and Capital Allocation

Beyond the financial results, the Board approved several strategic initiatives aimed at long-term growth. The company allotted 1,030,775 equity shares to employees under the Viyash Scientific Limited Employee Stock Option Scheme 2026 at an exercise price of ₹101 per share. This allotment increased the issued and paid-up capital to ₹879.81 million. The grant of 13.09 million stock options resulted in an incremental non-cash expense of approximately ₹193 million recognized under employee benefits.

Additionally, the Board authorized the incorporation of a wholly owned step-down subsidiary in Vietnam through Alivira Animal Health Limited (AAHL). The new entity will focus on importing, registering, and marketing animal health products and phytogenic solutions in the Vietnamese market, with an initial investment cap of USD 400,000. This move signals Viyash Scientific's intent to deepen its footprint in emerging Asian markets.

Strengthening Subsidiary Capital Structure

In a move to optimize its balance sheet, the Board approved the subscription of equity shares in its wholly owned subsidiary, Alivira Animal Health Limited (AAHL), via a rights issue. The consideration of up to ₹400.02 million will be adjusted against existing intercompany loans extended by Viyash Scientific. This conversion is designed to strengthen AAHL's capital structure and reduce its interest burden without requiring fresh cash infusion from the parent company. The indicative timeline for completion is August 30, 2026.

What the Numbers Show

The significant divergence between revenue growth (19.5%) and profit growth (115%) highlights improved operational efficiency and margin expansion in Q1FY26. The absence of exceptional items related to the amalgamation scheme in the current quarter, compared to ₹12.50 million in costs during Q1FY25, further contributed to the bottom-line surge. However, investors should note the incremental non-cash expense of approximately ₹193 million recognized under employee benefits due to the ESOP grant, which may impact future earnings per share calculations as these vest.

Viyash Viyash Scientific Limited (formerly Sequent Scientific Limited) will host a conference call with analysts and investors on Wednesday, August 12, 2026, at 3:30 PM IST to discuss its financial results for the quarter ended June 30, 2026. The announcement, made pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, provides stakeholders with a direct channel to review the company’s performance in Q1FY27.

The conference call aims to provide clarity on the company’s operational and financial trajectory for the initial quarter of the fiscal year. By engaging directly with market participants, management intends to address queries regarding revenue generation, cost structures, and strategic initiatives undertaken during the period. This transparency is critical for investors assessing the company’s near-term outlook and long-term growth potential in the scientific equipment and services sector.

Key leadership figures from Viyash Scientific Limited are confirmed to participate in the discussion. Dr. Hari Babu Bodepudi, Managing Director & Group CEO, will lead the session, providing overarching strategic context. He will be joined by Mr. Rajaram Narayanan, Executive Director and CEO – Animal Health, who is expected to elaborate on segment-specific performance. Mr. Ramakant Singani, Chief Financial Officer, will likely address the detailed financial metrics, cash flow dynamics, and balance sheet health presented in the quarterly filing.

Conference Call Details

Participants can access the call via the provided dial-in numbers. Early registration is facilitated through a Diamond Pass link available on the company’s investor relations portal.

The details of the conference call have been submitted to both BSE Limited and the National Stock Exchange of India Limited. The information is also publicly available on the Investors Section of the company’s website at www.viyash.com . Yoshita Vora, Company Secretary & Compliance Officer, signed the intimation letter dated August 3, 2026, ensuring regulatory compliance.

What This Means for Investors

The scheduling of this earnings call marks a standard but significant step in the corporate reporting cycle. For investors, the primary value lies in the qualitative commentary that accompanies the quantitative data. While the financial statements provide the hard numbers, the management’s narrative during the call often reveals insights into order book visibility, supply chain challenges, or shifts in customer demand that are not immediately apparent from the raw figures. Analysts will closely monitor any guidance provided for the remainder of FY27, particularly regarding margin sustainability and capital expenditure plans.